Novartis to seek full FDA approval for IgAN drug Vanrafia despite missing ph. 3 kidney function goal
It’s déjà vu all over again. Just as the kidney disease space becomes increasingly competitive, Novartis has found itself intending to turn a statistical miss into a regulatory win. | It’s déjà vu all ...
Novartis posts positive phase III ALIGN data for Vanrafia in IgAN, showing slower kidney decline as it eyes full approval in 2026.
Celebrate International Day of Women and Girls in Science 2026 by discovering some of the most influential women shaping biotech today.
Ultomiris (ravulizumab-cwvz) is a prescription drug used to treat certain rare inflammatory conditions. Ultomiris can cause side effects that range from mild to serious. Examples include headache, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results